ClinicalTrials.gg
Not yet recruitingNCT07569367ReMoTeUpdated Oct 13, 2026

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

An observational study in Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD) and Corticobasal Degeneration, sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionFrontotemporal DementiaRegistry: Frontotemporal Lobar DegenerationReclassifiedWhy we changed it
Registry
Frontotemporal Lobar Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Frontotemporal Dementia
Why
  1. The study's listed conditions name Frontotemporal Dementia, a narrower term within Frontotemporal Lobar Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioSensics · Observational

How we know

Updated Oct 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Planned enrollment
23rd of 37
60 · median 201
Started
2026
with 4 others
Observational
37 of 103
12 open now
Primary completion
2030-08
later than 34 of 44 live
Registered
103rd of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 23rd largest by planned enrollment of the 37 observational ones that give a count, is one of 5 that started in 2026, is one of 37 observational ones, reaches primary completion later than 34 of the 44 other live ones, and was the 103rd registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.

Read the detailed description

Frontotemporal degeneration (FTD) spans the spectrum of rare neurodegenerative disorders affecting movement, behavior, and cognitive function. FTD represents a group of disorders including progressive supranuclear palsy (PSP - a severe and rapidly progressive FTD disorder estimated to affect at least 20,000 Americans), frontotemporal dementia (FTD, the second most common cause of early-onset (\<65) dementia), primary progressive aphasia (PPA), semantic dementia (SD), and corticobasal syndrome (CBS). The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes. Sixty patients with FTLD syndromes will be recruited from Johns Hopkins University School of Medicine and Massachusetts General Hospital to participate in this 24-month study with visits every 6 months. The investigators aim to assess the correlation between outcomes as measured by the PAMSys pendant and PAMSys ULM wrist monitoring sensors, and clinical/functional assessments used for FTLD syndromes (behavioral variant frontotemporal dementia (bvFTD), non-fluent primary progressive aphasia (nfPPA), SD, and CBS), including the FTD Rating Scale (FTDRS), Cortical Basal Ganglia Functional Scale (CBFS), PSP Rating Scale (PSPRS), Frontotemporal lobar degeneration - Clinical Dementia Rating (FTLD-CDR) , modified Interpersonal Reactivity Index (mIRI Perspective Taking and Empathic Concern subscales summed to obtain a total Empathy score), the Pyramids and Palm Trees test (PPT), the Bedside Western Aphasia Battery-Revised (BWAB-R), phonemic fluency, and category fluency, in individuals with different stages of FTLD disease severity. The results will be used to develop and validate monitoring symptoms and function in FTLD syndromes. In an exploratory aim, the caregiver burden (Zarit Burden Inventory) and its relationship to patients' empathy levels (mIRI) will be assessed. The secondary objective of this study is to conduct free-flowing interviews with participants and clinical experts using the Technology Acceptance Model (TAM). This approach will help us examine perceptions of benefit, technology acceptance, technological anxiety, trust, facilitating conditions, perceived risk, and attitudes towards use from the perspectives of both patients and clinicians.

03

Conditions studied

  • Frontotemporal Lobar Degeneration (FTLD)
  • Frontotemporal Dementia (FTD)
  • Corticobasal Degeneration
  • Corticobasal Syndrome (CBS)

Browse trials for

Keywords

  • digital health
  • wearable sensors
  • frontotemporal lobar degeneration
04

In context

Frontotemporal Dementia Reclassified

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 73 observational studies indexed under Frontotemporal Dementia.

Browse Frontotemporal Dementia studies →

Lead sponsor

BioSensics is the lead sponsor of 12 studies on the registry; 8 are open to participants now.

Compared within Frontotemporal Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Frontotemporal Lobar Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study intends to enroll a diverse population of individuals representative of the general FTLD syndrome population. There are no restrictions based on race or ethnic origin. This study will enroll both male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.
  • Participants must be fluent in reading and speaking English and must be capable of providing based on the principal investigator's judgment.
  • Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.
  • Individuals who have a history of frequent falls defined as more than 5 falls per month.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Frontotemporal Lobar Degeneration (FTLD)

    60 patients who have a clinical diagnosis of possible or probable FTLD syndrome phenotype.

07

What researchers measure

Primary outcomes

  1. Physical Activity Monitoring

    Following each clinical visit, participants will be asked to wear a PAMSys pendant sensor and two PAMSys ULM wrist sensors for 14 days at home. The average daily number of steps will be measured using the PAMSys pendant.

    Time frame: 24 months

  2. Hand Function Monitoring

    Following each clinical visit, participants will be asked to wear two PAMSys ULM wrist sensors for 14 days at home. Average daily number of hand goal-directed movements will be measured using the PAMSys ULM wrist sensors.

    Time frame: 24 months

Secondary outcomes

  1. Zarit Burden Interview (ZBI-22)

    The Zarit Burden Interview is completed by a reliable caregiver. The ZBI scores range from 0-88, where 88 represents a worse outcome.

    Time frame: 24 months

  2. Montreal Cognitive Assessment (MoCA)

    This is a brief global cognitive screening assessment. Scores range from 0 to 30 where 0 represents a worse outcome.

    Time frame: 24 months

  3. Cortical Basal Ganglia Functional Scale (CBFS)

    The CBFS is a rating scale that evaluates experiences in daily living (EDLs) and consists of 14 questions on Motor EDLs and 17 questions on Non-Motor EDLs, each of which are rated on a Likert 5-point scale rating function from 0 to 4, where 0 = Normal or no problems and 4 = Severe problems. The questions are for the patient, but should be answered by both the patient and their caregiver together.

    Time frame: 24 months

  4. Progressive Supranuclear Palsy Rating Scale (PSPRS)

    The Progressive Supranuclear Palsy Rating Scale (PSPRS) is a 28-item clinical assessment used to measure the severity and progression of progressive supranuclear palsy (PSP). Out of the 28 items, 6 are scored on a 3-point scale (0-3) and 22 are scored on a 4-point scale (0-4). The PSPRS ranges from a score of 0-100 with a higher score representing greater impairment from the disease.

    Time frame: 24 months

Other outcomes

  1. Digital Speech Assessment

    Using a study tablet, participants will perform a series of digital speech assessments. The collected speech data will be analyzed using BioDigit Speech, an automatic speech analysis software developed by BioSensics.

    Time frame: 24 months

  2. Digital Cognitive Assessments

    Using a study tablet, participants will perform a series of digital cognitive assessments.

    Time frame: 24 months

  3. Digital Fine Motor Control Assessment

    Using a study tablet, participants will perform a series of tapping tests.

    Time frame: 24 months

08

Study locations

2 sites
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2030, 45 months later.

Of 46 observational studies under Frontotemporal Dementia, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 44. This study's planned 45 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartEst.
Nov 1, 2026was Aug 2026
Primary completionEst.
Aug 15, 2030
CompletionEst.
Dec 15, 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Nov 1, 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07569367
Lead sponsor
BioSensics
Collaborators
Johns Hopkins University, Massachusetts General Hospital, United States Department of Defense
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 15, 2030 (estimated)
Completion
Dec 15, 2030 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion